IGEM Therapeutics
Immuno-Oncology company developing novel IgE antibodies to treat cancer.
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 900 % | (20 %) | (64 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1538 %) | (162 %) | (450 %) | (989 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1366 %) | (123 %) | (416 %) | (972 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Epsilogen is a pioneering biotechnology company focused on the development of immunoglobulin E (IgE) antibodies to treat cancer, specifically targeting solid tumors. Operating in the biopharmaceutical sector, Epsilogen serves healthcare providers and patients seeking advanced cancer therapies. The company's business model revolves around the research, development, and commercialization of IgE-based drugs. Epsilogen generates revenue through government funding, partnerships, and eventual sales of its therapeutic products. The company’s lead candidate, MOv18 IgE, is the first IgE drug to enter clinical trials, showcasing its innovative approach. Epsilogen's IgE antibodies offer greater potency, enhanced tumor access, and a long tissue half-life, making them ideal for cancer treatment. The company continues to expand its diverse pipeline of IgE-based drugs, aiming to revolutionize cancer immunotherapy.
Keywords: IgE antibodies, cancer treatment, solid tumors, biotechnology, immunotherapy, MOv18 IgE, clinical trials, biopharmaceutical, healthcare, innovative therapies.